These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23864527)

  • 1. Feasibility of implementing a comprehensive warfarin pharmacogenetics service.
    Nutescu EA; Drozda K; Bress AP; Galanter WL; Stevenson J; Stamos TD; Desai AA; Duarte JD; Gordeuk V; Peace D; Kadkol SS; Dodge C; Saraf S; Garofalo J; Krishnan JA; Garcia JG; Cavallari LH
    Pharmacotherapy; 2013 Nov; 33(11):1156-64. PubMed ID: 23864527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of inpatient models of pharmacogenetics programs.
    Cavallari LH; Lee CR; Duarte JD; Nutescu EA; Weitzel KW; Stouffer GA; Johnson JA
    Am J Health Syst Pharm; 2016 Dec; 73(23):1944-1954. PubMed ID: 27864202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacogenetics service experience for pharmacy students, residents, and fellows.
    Drozda K; Labinov Y; Jiang R; Thomas MR; Wong SS; Patel S; Nutescu EA; Cavallari LH
    Am J Pharm Educ; 2013 Oct; 77(8):175. PubMed ID: 24159216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.
    Roper N; Storer B; Bona R; Fang M
    J Mol Diagn; 2010 May; 12(3):283-91. PubMed ID: 20228265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
    Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
    Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin pharmacogenetics.
    Limdi NA; Veenstra DL
    Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.
    Makar-Aušperger K; Krželj K; Lovrić Benčić M; Radačić Aumiler M; Erdeljić Turk V; Božina N
    Ther Drug Monit; 2018 Jun; 40(3):362-368. PubMed ID: 29494423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
    Leary E; Brilliant M; Peissig P; Griesbach S
    Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing.
    Zolekar A; Kim K; Lee JC; Han J; Duarte JD; Galanter WL; Cavallari LH; Nutescu EA
    Pharmacogenomics; 2022 Jan; 23(2):85-95. PubMed ID: 35001645
    [No Abstract]   [Full Text] [Related]  

  • 15. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.
    You JH; Chan FW; Wong RS; Cheng G
    Thromb Haemost; 2004 Sep; 92(3):590-7. PubMed ID: 15351856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.